Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
View Full Paper
Ask AI
Bookmark
Share
Discussion
Loading...
Member takes
Overview
Key Points
Key points are not available for this paper at this time.